Health Condition 1: C348- Malignant neoplasm of overlappingsites of bronchus and lung
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Intervention4: Nil: Nil
Intervention5: Nil: Nil
Intervention6: Nil: Nil
Sponsors
MOC Cancer Care and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Histologically or cytologically confirmed diagnosis of stage IV non-snmall cell lung cancer (NSCLC). Actionable Mutation-negative (EGFR, ALK, ROS, MET, NTRK, RET) and molecularly na ve (no prior molecular testing for actionable mutations or targeted therapy). Age more than 18 years. Either of the Gender. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. No prior systemic therapy for mnetastatic disease (first cycle taken before testing will be included). Except treated asymptomatic stable Brain metastasis. Ability to provide written informed consent and comply with study procedures. Patients willing to undergo regular cfDNA testing and PET-CT scans as part of study monitoring.
Exclusion criteria
Exclusion criteria: Eastern Cooperative Oncology Group (ECOG) performance status of more than 2. Patients with mutations or other actionable molecular alterations that would qualify for targeted therapy. Symptomatic Brain Metastasis. Patients with previous treatment for metastatic NSCLC. Patients with other active malignancies. Pregnant or breastfeeding women. Inability to undergo cfDNA testing or PET-CT scans due to technical or logistical reasons. Any other condition that, in the investigators opinion, would make the patient unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate whether rising cfDNA/ctDNA levels can identify molecular progressive disease (mPD) cutoff earlier than conventional radiological assessment.Timepoint: follow up every three months | — |
Secondary
| Measure | Time frame |
|---|---|
| The Secondary endpoints Overall Survival, Quality of Life (QOL) assessed using validated questionnaires.Timepoint: at baseline & on completion of treatment | — |
Countries
India
Contacts
Public ContactDr Udip Maheshwari
MOC Cancer Care and Research Centre
Outcome results
None listed